Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab (PH), lapatinib (L)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lux, Michael P., Nabieva, Naiba, Hartkopf, Andreas D., Huober, Jens, Volz, Bernhard, Taran, Florin-Andrei, Overkamp, Friedrich, Kolberg, Hans-Christian, Hadji, Peyman, Tesch, Hans, Häberle, Lothar, Ettl, Johannes, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W., Belleville, Erik, Wimberger, Pauline, Hielscher, Carsten, Geberth, Matthias, Abenhardt, Wolfgang, Kurbacher, Christian, Wuerstlein, Rachel, Thomssen, Christoph, Untch, Michael, Fasching, Peter A., Janni, Wolfgang, Fehm, Tanja N., Wallwiener, Diethelm, Schneeweiss, Andreas, Brucker, Sara Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357172/
https://www.ncbi.nlm.nih.gov/pubmed/30577662
http://dx.doi.org/10.3390/cancers11010010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357172/
https://www.ncbi.nlm.nih.gov/pubmed/30577662
http://dx.doi.org/10.3390/cancers11010010

Ejemplares similares